FLT-3 inhibitor monotherapy has been shown to achieve complete responses (CRs) and prolong survival in relapsed/refractory (R/R) FLT-3 mutant AML and to a lesser extent, FLT3-wild type AML [14,15]. The gene discussed is FLT3; the disease is acute myeloid leukemia.